Trial/Follow-up | Â | n | Mean (s.e.) |
---|---|---|---|
Clinical Trial 1 | Â | Â | Â |
8 Weeks | None/Minor | 59 | 80.5 (1.6) |
 | Mild | 159 | 80.3 (1.0) |
 | Moderate | 59 | 82.0 (1.6) |
 | Severe | 13 | 87.5 (3.5) |
Clinical Trial 2 | Â | Â | Â |
4 Weeks | None/Minor | 237 | 82.4 (0.8) |
 | Mild | 219 | 81.8 (0.9) |
 | Moderate | 160 | 82.5 (1.0) |
 | Severe | 33 | 82.3 (2.2) |
8 Weeks | None/Minor | 234 | 83.4 (0.9) |
 | Mild | 219 | 82.1 (0.9) |
 | Moderate | 155 | 83.7 (1.1) |
 | Severe | 35 | 82.3 (2.3) |
12 Weeks | None/Minor | 231 | 84.4 (0.9) |
 | Mild | 217 | 83.1 (1.0) |
 | Moderate | 151 | 85.8 (1.2) |
 | Severe | 34 | 82.5 (2.4) |
16 Weeks | None/Minor | 229 | 86.0 (0.9) |
 | Mild | 211 | 84.8 (1.0) |
 | Moderate | 153 | 88.4 (1.2) |
 | Severe | 32 | 86.8 (2.5) |
Clinical Trial 3 | Â | Â | Â |
4 Weeks | None/Minor | 40 | 76.0 (3.0) |
 | Mild | 21 | 73.7 (3.9) |
 | Moderate | 79 | 72.8 (2.0) |
 | Severe | 84 | 70.9 (2.0) |
12 Weeks | None/Minor | 37 | 76.9 (3.2) * |
 | Mild | 17 | 71.9 (4.5) |
 | Moderate | 71 | 74.0 (2.3) |
 | Severe | 69 | 64.3 (2.4) |
24 Weeks | None/Minor | 37 | 74.5 (3.5) |
 | Mild | 18 | 69.6 (4.8) |
 | Moderate | 68 | 72.4 (2.5) |
 | Severe | 74 | 67.4 (2.4) |